TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy

Area of Science:

• Immunology
• Gene Therapy
• Oncology

Background:

• Adoptive immunotherapy utilizes gene-modified T cells to combat diseases.
• Graft-versus-host disease (GvHD) is a significant complication of adoptive immunotherapy.
• Current suicide gene strategies, like scHSVtk, have limitations.

Purpose of the Study:

• To develop improved suicide gene variants for T cell therapies.
• To overcome the limitations of the wild-type splice-corrected herpes simplex virus thymidine kinase (scHSVtk) gene.
• To evaluate the efficacy and safety of novel TK.007 suicide gene.

Main Methods:

• Generated two new herpes simplex virus thymidine kinase (HSVtk) variants: coHSVtk and TK.007.
• Transduced human hematopoietic cell lines and primary T cells using retroviral vectors.
• Assessed in vitro expression, toxicity, and ganciclovir (GCV)-mediated killing.
• Evaluated TK.007 efficacy in murine allogeneic transplantation models.

Main Results:

• TK.007 demonstrated higher expression levels and sustained long-term expression with lower nonspecific toxicity compared to scHSVtk.
• TK.007 exhibited significantly improved kinetics of GCV-mediated cell killing in vitro.
• In vivo studies showed TK.007 effectively abrogated GvHD in a murine model.
• TK.007 mediated faster and more potent cell killing at lower GCV concentrations than scHSVtk.

Conclusions:

• The novel TK.007 suicide gene offers superior killing performance and reduced nonspecific toxicity.
• TK.007 represents a promising alternative for suicide gene therapy in adoptive immunotherapy.
• This advancement could improve the safety and efficacy of T cell-based treatments for GvHD.